(Q73867748)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

The potential of active metabolites of antihistamines in the management of allergic disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

M M Abdelaziz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

O A Khair

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

J L Devalia

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 May 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

425-434

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

Assessment of urticaria and angio-oedema

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

ABC of allergies. Allergy and the skin. I--Urticaria

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

The response of plasma histamine to bronchoprovocation with methacholine, adenosine 5'-monophosphate, and allergen in atopic nonasthmatic subjects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Mediator release during nasal provocation. A model to investigate the pathophysiology of rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Inflammatory mediators in late antigen-induced rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Measurement of histamine in nasal lavage fluid: comparison of a glass fiber-based fluorometric method with two radioimmunoassays

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

In vivo antigen-induced cutaneous mediator release: Simultaneous comparisons of histamine, tryptase, and prostaglandin D2 release and the effect of oral corticosteroid administration†

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Determinants of in vivo histamine release in cutaneous allergic reactions in humans

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Activation by histamine of bronchial epithelial cells from nonasthmatic subjects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

A new classification of H1-receptor antagonists.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Non-cardiac adverse effects of antihistamines (H1-receptor antagonists).

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Antihistamines and nasal blockage

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

CNS effects of histamine H1 antagonists

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

The systemic safety of fexofenadine HCl.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Cardiovascular safety of fexofenadine HCl.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Management of rhinitis--the specialist's opinion.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

A parallel-group comparison of astemizole and loratadine for the treatment of perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Safety and efficacy of loratadine in urticaria

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

A Comparison of Central and Peripheral Effects of Cetirizine and Loratadine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Comparative tolerability of second generation antihistamines

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Clinical pharmacology of new histamine H1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

1 reference

7 January 2021

Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Loratadine reduces allergen-induced mucosal output of alpha 2-macroglobulin and tryptase in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Beyond the histamine receptor: effect of antihistamines on mast cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Overview of allergic mechanisms. Ebastine has more than an antihistamine effect

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Cetirizine exerts anti-inflammatory effects on human neutrophils

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Effects of Cetirizine on Human Eosinophil and Neutrophil Activation in vitro

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

The effects of cetirizine on the adhesion of human eosinophils and neutrophils to cultured human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Adhesion receptors of the immune system

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

The role of intercellular adhesion molecule-1 in chronic airway inflammation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Continuous versus on demand treatment with cetirizine for allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00114.X

7 January 2021

10.1034/J.1398-9995.2000.00114.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10843422%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference